- Policy
- Hemophilia Type A tx, Bayer's Jivi has been approved
- by Lee, Hye-Kyung Jul 10, 2022 03:35pm
- Bayer's hemophilia type A treatment Jivi has been approved for domestic items. The MFDS recently granted Jivi to routine prophylaxis for on-demand and suppression of bleeding episodes in adults and adolescents (blood coagulation factor VIII birth deficiency) who have been treated before, management of bleeding before and after surgery, and r
- Product
- Sell Saxenda directly after non-face-to-face treatment?
- by Jung, Heung-Jun Jul 10, 2022 03:31pm
- Can hospitals sell Saxenda, known as diet injections, directly to patients after non-face-to-face treatment? It is an expensive drug worth more than 100,000 won per unit and there is a high demand for purchase, so it is not prescribed for outpatients. The problem is that some hospitals sell and deliver directly to patients even in non-face-to
- Company
- Byung-Jae Yoo to head integrated Novartis Korea
- by Eo, Yun-Ho Jul 8, 2022 06:25am
- Byung-Jae Yoo (49) was appointed the head of the integrated Novartis Korea. Suhee Shin, General Manager of the Oncology Business Unit at Novartis submitted her resignation. According to industry sources, Novartis Korea has been integrating its Pharmaceuticals and Oncology Business Unit with the goal of completing the integration within th
- Opinion
- [Reporter’s View] COVID-19 trials still in smooth progress?
- by Kim, Jin-Gu Jul 8, 2022 06:25am
- COVID-19 developers have been announcing that they will discontinue their clinical trials one after another. In just 10 days, Celltrion, Chong Kun Dang, and CrystalGenomics publicly announced that they will discontinue their COVID-19 clinical trials. When counting from January, the number increases to 5 with Genexine and HK Inno.N. The n
- Company
- Dong-A ST prepares to make another leap with Actonel
- by Eo, Yun-Ho Jul 7, 2022 05:55am
- Dong-A ST is attempting to make another leap with ‘Actonel,’ a bisphosphonate drug that is now sold exclusively by the company. According to industry sources, Dong-A ST has been working to land Sanofi’s bisphosphonate osteoporosis treatment Actonel (risedronate) at major medical institutions in Korea after it started to exclusively sup
- Company
- Two pharmaceutical unions unite with each other
- by Jul 7, 2022 05:54am
- With the birth of the nation's largest pharmaceutical industry union, the number of unions affiliated with the Federation of Korean Trade Unions in the pharmaceutical industry has increased to two. This includes corporate unions that have withdrawn from the existing industrial unions, drawing keen attention to the background. The NPU was l
- Company
- First KRAS lung cancer drug Lumakras released next month
- by Jul 7, 2022 05:54am
- Non-small cell lung cancer patients with KRAS mutations are expected to be able to receive treatment with the targeted anticancer therapy ‘Lumakras (sotorasib)’ starting this August. Amgen announced it will actively increase diagnostic tests and pursue reimbursement listing for the drug to increase accessibility to the only KRAS-targeted thera
- Company
- Novonodisk labor union announces union struggle on 7th
- by Eo, Yun-Ho Jul 7, 2022 05:54am
- Novonodisk Pharmaceutical's labor union under the NPU will hold regular general meetings and fight for all members. Novonodisk labor union is currently fighting against ▲ wage negotiations broke down in 2021, ▲petition of the Ministry of Labor regarding wage arrears due to the change in the disadvantage of the sales department incentive sys
- Policy
- The MFDS announced the designation of 4 temporary narcotics
- by Lee, Hye-Kyung Jul 7, 2022 05:54am
- The MFDS (Director Oh Yoo-kyung) announced on the 5th that it will designate four types, including 1V-LSD, which are used as substitute substances for drugs. 1V-LSD is newly designated as Class I temporary drug, and CH-PIATA is newly designated as Class II temporary drug. 1V-LSD has a structure similar to that of LSD and is a material whic
- Company
- Next-gen breast cancer drug, pneumococcal vaccine to come
- by Jul 6, 2022 05:47am
- New big drugs, including a pneumococcal vaccine, a macular degeneration treatment, and a breast cancer treatment, are expected to receive approval from the Ministry of Food and Drug Safety in the second half of this year. According to industry sources on the 6th, new drugs such as ▲Vaxneuvance (MSD) ▲Enhertu (Daiichi Sankyo) ▲Vabysmo (Roch
